Pharma/Biotech Patent Litigation Conference

Expert practitioners with vast experience in managing complex patent litigation will provide practical and strategic advice on:

• How to approach settlement agreements in the wake of uncertainty resulting from the EC Sector Inquiry
• The current status of obviousness in the EU and US post KSR and Angiotech
• Case law updates including HGS, Lundbeck and Esai v Dr Reddy's
• Improving your approach to litigation across the EU through assessment of recent judicial decisions
• Aligning your litigation strategy with corporate goals
• Mastering the challenges of coordinating information flow and legal teams across borders during litigation

Sean-Paul Brankin will speak on "The EU Sector Inquiry: Implications for Patent Litigation and Settlements".

• Review of the current climate: the impact of the Inquiry to date
• The implications of the Commission’s Preliminary Report for patent litigation and settlement
• What is the appropriate approach in this area pending the Final Report?
• The role of anti-trust in the pharma sector going forward